UBS Group’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.1M | Buy |
283,544
+225,676
| +390% | +$6.25M | ﹤0.01% | 3213 |
|
|
2025
Q4 | $891K | Sell |
57,868
-21,640
| -27% | -$431K | ﹤0.01% | 5674 |
|
|
2025
Q3 | $1.63M | Sell |
79,508
-58,772
| -43% | -$1.18M | ﹤0.01% | 5154 |
|
|
2025
Q2 | $2.77M | Buy |
138,280
+67,844
| +96% | +$1.28M | ﹤0.01% | 4472 |
|
|
2025
Q1 | $1.39M | Sell |
70,436
-16,752
| -19% | -$361K | ﹤0.01% | 5011 |
|
|
2024
Q4 | $1.96M | Buy |
87,188
+59,506
| +215% | +$1.54M | ﹤0.01% | 4731 |
|
|
2024
Q3 | $707K | Buy |
27,682
+7,564
| +38% | +$175K | ﹤0.01% | 4960 |
|
|
2024
Q2 | $470K | Sell |
20,118
-6,717
| -25% | -$141K | ﹤0.01% | 5048 |
|
|
2024
Q1 | $472K | Buy |
+26,835
| New | +$412K | ﹤0.01% | 5250 |
|
|
2023
Q4 | – | Sell |
-105
| Closed | -$1.43K | – | 9445 |
|
|
2023
Q3 | $1.43K | Buy |
105
+24
| +30% | +$404 | ﹤0.01% | 7943 |
|
|
2023
Q2 | $1.65K | Sell |
81
-253
| -76% | -$5.11K | ﹤0.01% | 7879 |
|
|
2023
Q1 | $7.32K | Sell |
334
-377
| -53% | -$7.67K | ﹤0.01% | 7817 |
|
|
2022
Q4 | $11.6K | Buy |
+711
| New | +$11.4K | ﹤0.01% | 8374 |
|
|
2022
Q1 | – | Sell |
-1,121
| Closed | -$10K | – | 10406 |
|
|
2021
Q4 | $10K | Buy |
+1,121
| New | +$14.7K | ﹤0.01% | 8771 |
|
|
2021
Q3 | – | Sell |
-536
| Closed | -$17K | – | 9673 |
|
|
2021
Q2 | $17K | Buy |
536
+126
| +31% | +$3.91K | ﹤0.01% | 7504 |
|
|
2021
Q1 | $14K | Buy |
410
+131
| +47% | +$6.66K | ﹤0.01% | 7671 |
|
|
2020
Q4 | $25K | Buy |
+279
| New | +$23.4K | ﹤0.01% | 6775 |
|
|
2020
Q3 | – | Sell |
-391
| Closed | -$43K | – | 8081 |
|
|
2020
Q2 | $43K | Buy |
+391
| New | +$43.8K | ﹤0.01% | 5979 |
|
Other funds holding ELVN
O
PCH
CC
VPC
BG
VCM
FFM
